Comparison between preprandial vs. postprandial insulin aspart in patients with type 1 diabetes on insulin pump and real-time continuous glucose monitoring

Diabetes/metabolism Research and Reviews
P ThuillierVéronique Kerlan

Abstract

The objective was to compare glycemic control between preprandial and postprandial bolus administration (15 min before [PRE] or immediately after the meal [POST]) in patients with type 1 diabetes using insulin pump and real-time continuous glucose monitoring. Between September 2015 and February 2016, a single-centre, open randomized, 2-way crossover study of patients on bolus insulin aspart administration was conducted during two 14-day periods and according to 2 administration regimen schedules (PRE/POST or POST/PRE). Inclusion criteria were as follows: patients with type 1 diabetes, ≥18 and ≤ 65 years old, treated with insulin aspart using a Medtronic® insulin pump and trained on functional insulin therapy. Patients were randomly assigned to either regimen schedule. At the beginning of each period, each patient was provided with a standardized high fat meal. Primary outcome was the area under the curve for interstitial glucose above 140 mg/dL per minute (AUC > 140 mg/dL/min) during each period. Secondary outcomes were time spent in hypo/eu/hyperglycemia, glycemic variability indices, and AUC during 4 hours after high fat meal calculated with continuous glucose monitoring data. Twenty-two patients were included. Mean AUC > 140...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jun 29, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·G A BrunnerT R Pieber
Apr 12, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·H P ChaseS K Garg
Mar 11, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·G SchernthanerM A Birkett
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Louis MonnierClaude Colette
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Michael Brownlee, Irl B Hirsch
Jan 29, 2010·Diabetes Technology & Therapeutics·Andrea E ScaramuzzaGian Vincenzo Zuccotti
Mar 2, 2011·Diabetes Technology & Therapeutics·Alessandra De PalmaGian Vincenzo Zuccotti
Apr 25, 2013·Diabetes·F John Service
Jan 26, 2016·Clinical Diabetes : a Publication of the American Diabetes Association·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Jul 25, 2019·Diabetes Technology & Therapeutics·Stefan PleusGuido Freckmann
Jul 13, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·Tenele A SmithCarmel E Smart

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.